The Latest Cardiac and Vascular News
Company to Showcase Progress on Radical Catheter Portfolio and Best-in-Class Ribbon Technology Platform at Society of Neurointerventional Surgery Annual Meeting Company to Showcase Progress on Radical Catheter Portfolio and Best-in-Class Ribbon Technology Platform at Society of Neurointerventional Surgery Annual Meeting
Celebrating the bold leaders shaping the future through the world’s most ground-breaking companies WEST VALLEY, Utah, July 9, 2025 /PRNewswire/ — Ernst & Young LLP (EY US) today announced that John Lippert, Chief Technical Officer of Scientia Vascular was named an Entrepreneur Of The…
Cardiac amyloidosis is an often-missed, life-threatening cause of heart failure. As new disease-modifying therapies emerge, timely and earlier diagnosis is critical. EchoGo® Amyloidosis is the first FDA-cleared AI screening tool for cardiac amyloidosis using an echocardiogram and has…
– VitalStream wearable delivers real-time, beat-by-beat insights to help clinicians detect cardiovascular changes earlier and respond faster – SOMERSET, N.J., July 9, 2025 /PRNewswire/ — Terumo Health Outcomes (THO), a division of Terumo Interventional Systems (TIS), today announced a…
MIAMI, July 09, 2025 (GLOBE NEWSWIRE) — InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard Prime carotid stent system for the prevention of stroke, today announced the official commercial launch of the CGuard Prime carotid stent system in the U.S., following its premarket application (PMA) approval from the U.S. Food and Drug Administration (FDA).
The GORE® VIABAHN® VBX Balloon Expandable Endoprosthesis indication expansion brings the first bridging stent device with dual indication for both fenestrated and branched endovascular repair*. PUTZBRUNN, Germany, July 9, 2025 /PRNewswire/ — W. L. Gore & Associates (Gore) announces CE…
AGEPHA Pharma will supply LODOCO® (low-dose colchicine) for a Cardio Diagnostics-sponsored clinical study to explore the use of Cardio Diagnostics’ PrecisionCHD™ test to identify patients with inflammation-driven coronary heart disease (CHD) CHICAGO–(BUSINESS WIRE)–Cardio Diagnostics Holdings Inc. (NASDAQ: CDIO), a precision cardiovascular medicine company with a pioneering technology at the intersection of […]
– SGT-501 is a novel gene therapy for rare, life-threatening, genetic arrhythmogenic disease with no approved therapies –
BURLINGTON, Mass., July 08, 2025 (GLOBE NEWSWIRE) — LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its second quarter 2025 financial results on Tuesday, August 5, 2025, after the market close. The company has scheduled a conference call for 5:00 PM EDT the same day to discuss the results, business highlights, and company outlook.
Increasing rates of neurovascular interventions spark a need for reliable access and procedural versatility Company expands portfolio with a novel access catheter featuring a unique ID/OD ratio Purpose-built laser cut technology enables balanced delivery performance and stable support…
